Skip to Content

'
Ana Aparicio, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3512
Phone: (713) 792-2830
Fax: (713) 745-1625

Education & Training

Degree-Granting Education

1995 Universidad Autónoma de Madrid, Madrid, Spain, MD, Medicine

Postgraduate Training

7/2000-7/2003 Clinical Fellowship, Medical Oncology and Hematology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Keck School of Medicine, Los Angeles, CA
6/1998-6/2000 Clinical Residency, Internal Medicine, West Los Angeles VA Medical Center, UCLA School of Medicine, Los Angeles, CA
6/1997-6/1998 Clinical Internship, Internal Medicine, West Los Angeles VA Medical Center, UCLA School of Medicine, Los Angeles, CA
4/1996-4/1997 Clinical Internship, Medical Oncology, Hospital Universitario Doce de Octubre, Universidad Complutense de Madrid, Madrid, Spain

Board Certifications

2003 Medical Oncology, Recertification Date: 12/2014
2003 Hematology

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2013
Assistant Professor, Department of Medicine, Division of Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2004-2006
Clinical Instructor, Department of Medicine, Division Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2003-2004

Other Appointments/Responsibilities

Associate Member, Member of The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2007-present

Consultantships

Reviewer, Sanofi Oncology, Houston, 8/2014-present

Institutional Committee Activities

Faculty Representative, The University of Texas MD Anderson Cancer Center Faculty Senate, 9/2015-present
Associate Member, Institutional Review Board (IRB1), 2012-2015
Reviewer, Clinical Research Committee (CRC3), 2009-2011
Member/ Brazil, MD Anderson Cancer Center Faculty and MD Anderson Physician Network Host Affiliation of Multidisciplinary Conference, 2008-present
Member, MD Anderson Cancer Center Faculty and MD Anderson Physician Network Host Affiliation of Multidisciplinary Conference, 2008-2012

Honors and Awards

2013 Stand Up To Cancer and the Cancer Research Institute Young Investigator Award, American Association for Cancer Research
2010 Prostate Cancer SPORE Career Development Award, National Cancer Institute
2006 Clinical Research Career Development Award, American Society of Clinical Oncology
2002 Chief Fellow, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2002 Outstanding Fellow of the Year, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2002 Young Investigator Training Course, Southwest Oncology Group
2000 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1998 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1992 Erasmus Scholarship, European Community for Academic Excellence

Professional Memberships

American Association for Cancer Research
Member, 2003-present
American Medical Association
Member, 2016-present
American Society of Clinical Oncology
Member, 2003-present
Harris County Medical Society
Member, 2013-present
Southwest Oncology Group
Member, 2003-present
Texas Medical Association
Member, 2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 3/2016. e-Pub 11/2015. PMCID: PMC4794379.
2. Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. e-Pub 2/18/2016. PMID: 26890396.
3. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR-2 as targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, pii: clincanres.0235.2015, 1/1/2016. e-Pub 8/13/2015. PMCID: PMC4703437.
4. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD anderson experience. Oncogene 34(43):5411-7, doi: 10.1038/onc.2015.5, 10/2015. e-Pub 2/9/2015. PMCID: PMC4530091.
5. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, doi: 10.1016/j.clgc.2014.10.004., 6/2015. e-Pub 10/24/2014. PMID: 25465491.
6. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 1(121(1)):69-76, 1/1/2015. e-Pub 8/22/2014. PMCID: PMC4270821.
7. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67(1):53-60, 1/2015. e-Pub 5/29/2014. PMCID: PMC4247811.
8. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014). Sci Transl Med 6(252):252ra122, 9/2014. PMID: 25186177.
9. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-Ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 5/2014. PMCID: PMC4135429.
10. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
11. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/2012. PMCID: PMC3882163.
12. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3):895-903, 3/2012. e-Pub 1/2012. PMID: 22245216.
13. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling lethal prostate cancer variant with small cell carcinoma features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMCID: PMC3923417.
14. Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 7(11):e48787, 2012. e-Pub 11/2012. PMCID: PMC3511501.
15. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol 29(6):682-9, Nov-Dec, 11/2011. e-Pub 12/2009. PMID: 19959380.
16. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical and gene expression profiles. Prostate 71(8):846-56, 6/2011. e-Pub 11/2010. PMCID: PMC3883511.
17. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol 34(1):27-31, 2/2011. e-Pub 2/2010. PMID: 20142723.
18. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 1/2011. e-Pub 10/2010. PMID: 21040948.
19. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/2010. PMID: 19862815.
20. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. e-Pub 7/2009. PMCID: PMC2731785.
21. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate:clinical features and implications after local therapy. Cancer 115(13):2872-80, 7/2009. PMID: 19402048.
22. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3):176-84, 4/2009. e-Pub 4/2009. PMCID: PMC2848123.
23. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 4(2):48, 2009. e-Pub 8/2009. PMCID: PMC2731785.
24. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14(21):7138-42, 11/2008. PMCID: PMC3543872.
25. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 67(1):346-53, 1/2007. PMID: 17210717.
26. Aparicio A, Eads C, Leong L, Laird PW, Newman N, Weber JS. Phase I trial of continuous infusion 5-Aza-2'-deoxyctidine (DAC). Cancer Chemother Pharmacol 51(3):231-39, 3/2003. PMID: 12655442.
27. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2):220-29, 2/1998. PMID: 9519785.
28. Sankar MN, Wu, G, Lu JF, Hoang AG, Li NT, Elsa M, Broom BM, Baggerly, KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis CJ. The inhibitor of nuclear export selinexor activates tumor suppressors, inhibits androgen receptor, and induces regression of castration-resistant prostate cancer in vivo. Clin Cancer Res. Submitted.

Invited Articles

1. Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology (Williston Park) 28(10):831-8, 10/2014. e-Pub 10/2014. PMID: 25323607.
2. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846-50, 6/2014. e-Pub 4/2014. PMCID: PMC4040316.
3. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/2013. PMCID: PMC3926428.
4. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 8(10):562-8, 10/2011. e-Pub 8/2011. PMCID: PMC3641817.
5. Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncol 7(3)(3):447-63, 3/2011. PMID: 21417907.
6. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer 2011:580318, 2011. e-Pub 11/2011. PMCID: PMC3236424.
7. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7(5)(5):309-12, 3/2006. PMID: 16640801.
8. Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am 32(2):217-30, 5/2005. PMID: 15862619.
9. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457-63, 5/2004. PMID: 15164071.
10. Aparicio A, Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-35, 5/2002. PMID: 11937001.
11. Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3(4):627-33, 4/2002. PMID: 12090735.
12. Weber JS, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13(2):124-28, 3/2001. PMID: 11224710.
13. Tannir N, Plimack E, Ng, C, Pheroze T, Neby B, Lianchun X, Smith L, Zita L, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood C, Jonasch E. Tumor heterogeneity is reflected in the response of advance non-clear cell renal cell carcinomato sunitinib therapy. J Clin Oncol. Submitted.

Editorials

1. Logothetis CJ, Aparicio A. Is It Time to Re-Examine Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases? J Clin Oncol. In Press.
2. Chapin BF, McGuire SE, Aparicio AM. Local Therapy in Metastic Prostate Cancer: Does an Integrated Approach Improve Clinical Outcomes? 2015 Genitourinary Cancers Symposium Daily News(2), 2/2015.
3. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol 65(6):1067-8, 6/2014. e-Pub 12/2013. PMID: 24411278.
4. Goldkorn A, Aparicio AM, Quinn DI. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol 24(7):1717-20, 7/2013. PMID: 23798673.
5. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov 1(6):466-8, 11/2011. PMCID: PMC4133693.
Other Articles
1. Aparicio AM. Prostate Cancer: Clinical practitioner perspective. Endocrine News, 9/2011.
2. Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR, Asmar L, von Hoff DD. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5(7):457-9, 12/2007. PMID: 18272030.

Abstracts

1. Sumit Kumar Subudhi, Ana Aparicio, Patricia Troncoso, Jianhua Zhang, Curtis Gumbs, Chang-jiun Wu, Luis M Vence, Christopher Logothetis, Andrew Futreal, James Patrick Allison, Padmanee Sharma. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). J Clin Oncol 34(suppl; abstr e14506), 6/2016.
2. Paul Gettys Corn, Elsa Li Ning Tapia, Lianchun Xiao, Elisabeth I. Heath, Haidee Chancoco, Anh Hoang, Eleni Efstathiou, Timothy C. Thompson, Patricia Troncoso, Christopher Logothetis, Ana Aparicio. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). J Clin Oncol 34(suppl; abstr 5020), 6/2016.
3. Bruno C. Odisio, Jared Allen Christensen, Sumit Kumar Subudhi, Steven Huang, Sanjay Gupta, Kamran Ahrar, Rahul Sheth, Joe Ensor, Ana Aparicio. Image guided thermal ablation of prostate cancer metastases to the liver. J Clin Onco 34(suppl; abstr e16515), 6/2016.
4. Corn, PG, Tu SM, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A.. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(suppl; abstr 5010), 05/2015, 5/2015.
5. Chapin BF, McGuire S, Wang X, Sharma P, Troncosco P, Davis J, Navai N, Subudhi S, Zurita A, Araujo J, Pettaway C, Matin S, Pisters L, Ward J, Tu SM, Wang J, Ott L, Logothetis CJ, Aparicio Ana. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer. J Clin Oncol 33(suppl; abstr TPS5075), 5/2015.
6. Quinn DI, Ruel N, Twardowski PW, Groshen SG, Dorff TB, Pal SK, Stadler WM, Aparicio A, Lara PN, Newman, EM. Eribulin in advanced urothelial cancer (AUC) patients (pts): A california cancer consortium trial (NCI/CTEP 7435). J Clin Oncol 33(suppl; abstr 4504) (#146988), 5/2015.
7. Aparicio A, Shen L, Li Ning Tapia E, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn PG, Thompson TC, Broom BM, Baggerly KA, Logothetis CJ, Maity SN. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). J Clin Oncol 33(suppl; abstr 5055), 5/2015.
8. Aparicio A, Shen L, Li-Ning Tapia E, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Broom B, Baggerly K, Logothetis CJ, Maity S. A comprehensive molecular characterization of aggressive variant prostate cancer (PC). J Clin Oncol 33(suppl 7, abstr 149) (#141820), 2/2015.
9. Maity SN, Guanglin Wu G, Lu JF, Hoang A, Landesman Y, McCauley D, Carlson R, Rashal T, Shacham S, Broom BM, Baggerly KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis CJ. Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. J Clin Oncol 33(suppl 7, abstr 277), 2/2015.
10. Corn PG, Tu SM, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis CJ, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32(suppl 4 ; abstr 148), 2014.
11. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32(suppl; abstr e16046) (#e16046), 2014.
12. Aparicio A, Maity S, Wang X, Hoang AG, Efstathiou E, Troncoso P, Logothetis CJ,. A molecular characterization of the anaplastic prostate carcinomas. 2013 AACR Annual Conference (#7587), 4/2013.
13. Aparicio A, Gallichotte E, Cheng H, Yoo SY, Maity S, Logothetis CJ, Tewari M,. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. 2013 AACR Annual Conference (#5692), 4/2013.
14. Kleb BN, Estecio M, Wu G, Lu JF, Logothetis CJ, Maity S, Aparicio A. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. 2013 AACR Annual Conference 73(8 suppl; abst 2986) (#2986), 4/2013.
15. Corn PG, Varkaris A, Li Ning Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol 31 (#58), 2013.
16. Quinn DI, Hamid O, Tsao-Wei D, Hu J, Pinski J, Schuckerman A, Daneshmand S, Groshen S, Raghaven D, Korn C, Massopust K, Ketchens C, Aparicio AM, Dorff TB. Gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (PTS) with refractory germ cell carcinoma: A phase II study conducted at the University of Southern California. Ann Oncol 23(9):ix258-ix293 (#790O), 10/2012.
17. Aparicio A, Sun, J, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Radtke A, Sharma P,. A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma. Cancer Research 72(6) (#5368), 4/2012.
18. Kleb B, Estecio M, Zhang J, Tzelepi V, Chung, W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Aparicio A. The DNA methylome of castration-resistant prostate cancer. Cancer Research 72(8 suppl; abst 991) (#991), 4/2012.
19. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29 (#4666), 6/2011.
20. Tzeelpi V, Maity S, Zhang J, Liang S, Lu JF, Anh H, Kleb B, Efstathiou E, Navone N, Troncoso P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. Cancer Research 71(8):10.1158/1538-7445.AM2011-36 (#36), 4/2011.
21. Tzelepi V, Maity S, Zhang J, Karlou M, Liang S, Hoang A, Lu J, Kleb B, Efstathiou E, Navone N, Aparicio A, Troncoso P. Differential expression of UBE2C and ASCL1 in neuroendocrine carcinoma and adenocarcinoma of the prostate in xenograft models and human samples. USCAP Annual Meeting, San Antonio, TX, 2011.
22. Efstathiou E, Tu S, Aparicio A, Hoang A, Troncoso P, Smith L, Chieffo N, Molina A, Logothetis C,. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate(AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(15s) (#4547), 2010.
23. Jonasch E, Wood G, Matin S, Tamboli K, Do L, Pagliaro C, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s (#5104), 5/2008.
24. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC). J Clin Oncol 26(15S):271s (#16000), 5/2008.
25. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26(15S) (#5093), 2008.
26. Sonpavde G, Aparicio AM, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Williams A, Zhan F, Boehm KA, Asmar L, Von Hoff DD. Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. J Clin Oncol 26 (#5172), 2008.
27. Aparicio A, North B, Yang J, Jelinek J, Guo C, Logothetis C, Navone N, Issa JP. DNA methylation profiles can discriminate prostate cancer phenotypes. Gordon Research Conference, Ventura, CA, 2008.
28. Cheung EM, Quinn DI, Tsao-Wei DD, Groshen SG, Aparicio AM, Twardowski P, Shatta GS, Lara Jr. PN, Gandara DR. Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy--California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol 26(15S) (#16058), 2008.
29. Luu TH, Leong L, Morgan R, McNamara M, Lim D, Portnow J, Frankel P, Aparicio A, Chew H, Gandara DR, Somlo G. Vorinostat (suberoylanilide hydroxamic acid) as salvage therapy in metastatic breast cancer (MBC): A California Cancer Consortium phase II study. J Clin Oncol 25(18S) (#11502), 2007.
30. Ramalingam S, Parise RA, Egorin MJ, Argiris A, Stoller R, Beattie l, Aparicio A, Newman EM, Zwiebel J, Belani CP. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI # 6922). J Clin Oncol 24(18S) (#2077), 2006.
31. Dorff TB, Rupani R, Wei DT, Groshen S, Pinski J, Raghavan D, Quinn D, A. POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience. J Clin Oncol 24(18S) (#4591), 2006.
32. Barske L, Bollati V, Yang AS, Aparicio AM. A comparison of bisulfite-based DNA methylation assays for the measurement of DNA methylation changes induced by decitabine. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics:Discovery, Biology, and Clinical Applications, 2005.
33. Egger G, Aparicio A, Escobar S, Jones PA. Effects of combinatiorial treatment of T24 cells with 5-aza-2' deoxycytidine and 4-phenylbutyric acid. AACR 96th Annual Meeting Proceedings Vol 46 (#1819), 2005.
34. Aparicio A, Iqbal S, Yang D, Groshen S, Park A, Garcia A, Lenz HJ. Pilot trial of 5-Fu/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (lFL). J Clin Oncol, (Post-Meeting Edition) 14S((July 15 Supplement)) (#3773), 2004.

Book Chapters

1. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban DA, Efstathiou E, Aparicio A. 98 Neoplasm of the Prostate. In: Holland-Frei Cancer Medicine, 9th. Ed(s) Robert C. Bast, Carlo M. Croe, William N. Hait, Waun Ki Hong, Donald W. Kufe, Martine Piccart-Gebhart, Raphael E. Pollock, Ralph R. Weichselbaum, Hongwang Yang, James F. Holland. Wiley-Blackwell: Hoboken, New Jersey. In Press. ISBN: 978-1-118-93469-2.
2. Tagawa ST, Aparicio A, Robinson B, Sing-Batra J, Golden E. Uncommon Cancers of the Prostate. In: Textbook of Uncommon Cancers, 5th. In Press.
3. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasm of the Prostate. In: Cancer Medicine, 8th. People Medical Publishing House-USA: Shelton, CONN, 1228-1254, 2010.
4. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA, 2009.

Grant & Contract Support

Title: Integrative Molecular Characterization of Exceptional Responses to Existing and Emerging Therapies in Prostate Cancer
Funding Source: DOD-PCRP
Role: Co-Investigator
Principal Investigator: Futreal
Duration: 9/30/2016 - 9/29/2019
 
Title: A Candidate Signature to Predict Primary Tumor Progression: Towards the Integration of Local Therapy in the Management of De Novo M1 Prostate Cancer
Funding Source: DOD-PCRP Idea
Role: Principal Investigator
Duration: 9/1/2016 - 8/31/2019
 
Title: Function of RB1 Tumor Suppressor and Oncogenic Lineage-Specific Transcription Factors in the Pathogenesis of Small Cell Prostate Cancer
Funding Source: DOD-PCRP Idea
Role: Co-Investigator
Principal Investigator: Maity
Duration: 9/1/2016 - 8/31/2019
 
Title: MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Christopher Logothetis and Timothy Thompson
Duration: 4/1/2016 - 3/31/2021
 
Title: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer. Flagship Project 3: DNA Damage Response Targeted Therapies for Aggressive Variant Prostate Cancer
Funding Source: U.T. MD Anderson Prostate Cancer Moonshot
Role: Co-Investigator
Principal Investigator: Christopher Logothetis and Timothy Thompson
Duration: 9/1/2015 - 8/31/2016
 
Title: Project 1: Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC
Funding Source: MD Anderson Cancer Center
Role: Co-Investigator, Project 1
Principal Investigator: Christopher Logothetis
Duration: 3/1/2015 - 2/29/2016
 
Title: Project 1: Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC
Funding Source: U.T. MD Anderson Cancer Center Prostate Cancer SPORE
Role: Co-Investigator
Principal Investigator: Christopher Logothetis
Duration: 3/1/2015 - 11/30/2015
 
Title: Prostate Cancer Moonshot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer Flagship Project 2: Adaptive Androgen Signaling in mCRPC Effectively Targeted by Novel Androgen Signaling Inhibitors
Funding Source: U.T. MD Anderson Moonshot Program
Role: FP2 Subproject Leader
Duration: 9/1/2014 - 8/31/2015
 
Title: Reprogramming Small Cell Prostate Carcinomas Through EZH2 Inhibition To Develop Novel Therapeutic Strategies For Lethal Prostate Cancer
Funding Source: Institutional Research Grant (IRG)
Role: Principal Investigator
Duration: 1/1/2014 - 1/1/2015
 
Title: Reprogramming Small Cell Prostate Carcinomas Through EHZ2 Inhibitor to Develop Novel Therapeutic Strategies for Lethal Prostate Cancer
Funding Source: Center of Cancer Epigenetics (CCE) Pilot Project
Role: Principal Investigator
Duration: 9/1/2013 - 8/31/2014
 
Title: Reprogramming Small Cell Prostate Carcinomas Through EZH2 Inhibition To Develop Novel Therapeutic Strategies For Lethal Prostate Cancer
Funding Source: GlaxoSmithKline LLC
Role: Principal Investigator
Duration: 5/18/2013 - 6/30/2016
 
Title: Immunologic Checkpoint Blockage and Adoptive Cell Transfer in Cancer Therapy
Funding Source: American Association for Cancer Research (AACR)
Role: Young Investigator
Principal Investigator: Allison
Duration: 3/1/2013 - present
 
Title: Characterizing the Anaplastic Prostate Carcinomas
Funding Source: Texas Foundation Business Professional Women (TFBPW)
Role: Award Recipient
Duration: 2/2010
 
Title: Characterization of the Anaplastic Prostate Carcinomas
Funding Source: NIH-Spore-CDA
Role: Principal Investigator
Duration: 1/8/2010 - 8/31/2012
 
Title: Biomarkers of Epigenetic Therapy
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2010
 
Title: A Phase I Clinical Trial of Low Dose Decitabine and Sodium Phenylbutyrate in Patients with Solid Tumors, Relinquished on 07/01/06
Funding Source: Whittier Foundation
Role: Principal Investigator
Duration: 11/1/2004 - 9/1/2006
 
Title: Biologic Markers of Activity in Epigenetic Therapy in a Phase I Trial of Low Doses of Decitabine with Oral Sodium Phenylbutyrate in Patients with Solid Tumors, Relinquished on 07/01/06
Funding Source: Wright Foundation
Role: Principal Investigator
Duration: 7/8/2004 - 6/30/2005
 
Title: Pilot Study of Biomaker of Epigenetic Therapy in Peripheral Blood and Oral Mucosa Cells, Seed Grant Award, Relinquished on 07/01/06
Funding Source: Institutional Research Grant (IRG)
Role: Principal Investigator
Duration: - 11/19/2004

Last updated: 6/21/2016